Haisco opened a China Phase 3 for an oral IL-23. The category leader is already a pill.

Haisco did not invent the idea of swallowing an IL-23 drug. On 11 November China’s trial registry recorded a Phase 3 for its HSK47388 tablets in moderate-to-severe plaque psoriasis. The study is multicenter, randomized, and double-blind, planned for about 390 people. At week 16 the co-primary reads are PASI 90 and an investigator score of 0 or 1 with at least a two-point drop from baseline. Trade coverage called it the first China-originated oral IL-23 asset to reach Phase 3. That “first” is a domestic claim, and it is the right size.

The class clock is already on a pharmacy shelf elsewhere. Johnson & Johnson’s icotrokinra, an oral peptide aimed at the IL-23 receptor, was approved in the United States in March 2026 for psoriasis and later cleared in Europe. Haisco is opening a China efficacy study in a category whose reference product is no longer a biologic injection.

What Haisco has published in people is still a healthy-volunteer package, from January 2026. The company said the drug was tolerated, the pharmacokinetics looked linear, and the half-life ran about 16 to 18 hours—long enough to argue for once a day. A formulation with an absorption enhancer at 50 mg matched the exposure of a 200 mg immediate-release tablet, and taking it 30 minutes before food barely moved exposure. None of those sentences is a psoriasis patient reaching PASI 90.

The partnering question is therefore not whether Chengdu can enroll another immunology trial. It is whether an oral IL-23 from Haisco still has value outside China once the comparator is a marketed pill, and whether, inside China, dermatologists will wait on PASI data while IL-23 antibodies are already injectable. The registry entry starts that argument. It does not settle it.

Industry information only—not medical or investment advice.